RGEN Lags Peers as Put Buying Spikes Before Wednesday's Print

Repligen Corporation is the laggard in its peer group this week, dropping 1.7% while the median of its closest correlated names gained 6.9%, and that gap opens up into a quarterly earnings release scheduled for Wednesday afternoon.

Among the most correlated peers, Charles River Laboratories rose nearly 14% on the week and Tempus AI added 8%. Danaher and Thermo Fisher each closed modestly higher. Repligen, at $175.80, sits roughly 8% below the Street's mean price target of $202, a gap that widened as the stock shed 7.3% over the past month. That relative weakness is the backdrop for what has become a notably defensive options setup.

The sharpest signal this week is in options, where put demand has jumped to an unusual level. The put/call ratio reached 2.65 on Tuesday, more than 2.3 standard deviations above its 20-day average of 1.92. That is close to the most defensive reading of the past several months outside of a brief spike in mid-September. Whatever drove that earlier episode, the current move into puts is happening with one trading day left before results, pointing to investors actively buying downside protection rather than positioning for a bounce. The borrow market is not flashing the same alarm: availability runs at 250%, meaning shares to borrow are plentiful relative to the existing short position, and the cost to borrow has eased 15% over the past week to just 0.54%. Short interest, at 12.6% of the free float, ticked up roughly 1.3% over the week but is essentially flat over the past month. Lenders are not stressed; it is the options market doing the hedging.

The Street has generally been lifting targets into this print, though the rating picture is mixed. Barclays raised its target to $225 from $175 earlier this month while keeping its Overweight rating. Canaccord, by contrast, raised its target to $180 but held at Hold, leaving a target effectively at the current price. UBS and Barclays are the more optimistic voices at $225. The valuation has compressed alongside the share price: the price-to-earnings multiple has fallen by roughly 9 points over the past 30 days to 68.6x, and EV/EBITDA has dropped more than 7 turns to 42x. The ORTEX factor scores show a stock with genuine earnings momentum, ranking in the 82nd percentile on 30-day EPS momentum, but weak on value (EV/EBIT at the 3rd percentile) and analyst consensus differentiation (5th percentile). The short score of 65.7 has been broadly stable across the past two weeks, running in a narrow band, which argues against any fresh catalyst reshaping the bearish thesis from the short side.

On ownership, FMR (Fidelity) is the standout institutional holder, with 13% of shares and a reported addition of roughly 4 million shares in the quarter ending September 30. That is the largest single position change among the top ten holders. T. Rowe Price filed an amendment in August showing its stake had dropped from 8.2% to 3.1%, a significant reduction. Insider activity over the past 90 days shows net selling of roughly 32,900 shares at a combined value of about $6 million, but the CEO's sales were conducted under a pre-arranged 10b5-1 plan, the planned nature reducing their informational weight considerably. The one prior quarterly earnings reaction in the dataset, from the July 2026 print, produced a negligible next-day move of -0.16% followed by a 12.9% gain over the subsequent five sessions, though a single data point provides limited guidance on what Wednesday holds.

The level to watch is the $175 area where the stock has spent the past few sessions: a break or a hold after the print will resolve whether the put activity reflected well-placed caution or overcrowding in downside protection.